Give Abrysvo respiratory syncytial virus vaccine RSVpreF to pregnant pts at 32 36 wk gestation using seasonal administration Sept Jan in most of the U S to prevent RSV associated LRTI in infants

By rray, 31 October, 2023
Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> <b>CDC 2023.</b> Fleming-Dutra KE, et al. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. <i>MMWR Morb Mortal Wkly Rep.</i> 2023 Oct 13;72(41):1115-1122. <a href=https://www.cdc.gov/mmwr/volumes/72/wr/mm7241e1.htm><u>Free, full-text article</u></a>
Detail Type
Text
Detail Text
In jurisdictions w RSV seasonality that differs from that of most of the continental U S e g Alaska southern Florida Guam Hawaii Puerto Rico U S affiliated Pacific Islands U S Virgin Islands follow state local territorial guidance on timing of RSVpreF vac
May be administered w other recommended vaccines such as Tdap influenza and COVID 19 w o regard to timing including simultaneous vaccination at different anatomic sites on the same day
No data are available on the efficacy of the 1st lifetime dose to protect infants born after subsequent pregnancies or on the safety of additional doses given during subsequent pregnancies
Patient Type Detail Header (Long)
Give <a href=https://online.epocrates.com/e/deeplink/drugs/10a11148/Abrysvo><u><b>Abrysvo (respiratory syncytial virus vaccine (RSVpreF))</b></u></a> to pregnant pts at 32-36 wk gestation using seasonal administration (Sept.-Jan. in most of the U.S.) to prevent RSV-associated LRTI in infants <6 mo. <b>Don’t use Arexvy (RSVPreF3) in pregnant pts.</b>